Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company, has completed its acquisition of Optinose, Inc. The transaction, valued at approximately $330 million, will broaden Paratek's commercial portfolio to include Optinose's product XHANCE® alongside its flagship antibiotic, NUZYRA®. Optinose shareholders received $9 per share in cash and contingent value rights (CVRs) for up to $5 per share, contingent upon achieving certain revenue milestones with XHANCE. Following the merger approval by Optinose's shareholders, the company's common stock will be delisted from the Nasdaq Global Select Market. Paratek's CEO, Evan Loh, stated that the acquisition is a pivotal step towards establishing a multi-product specialty therapeutics company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.